Beneficial effects of sarpogrelate and rosuvastatin in high fat diet/streptozotocin-induced nephropathy in mice

PLoS ONE

Volumn 11, Issue 4, 2016, Pages

  Kim, Dong Hyun ^a   Choi, Bo Hyun ^a   Ku, Sae Kwang ^b   Park, Jeong Hyeon ^a   Oh, Euichaul ^a   Kwak, Mi Kyoung Kwak ^a  

^a The Catholic University of Korea   (South Korea)

^b Daegu Haany University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CD31 ANTIGEN; COLLAGEN TYPE 4; CYSTATIN C; PLASMINOGEN ACTIVATOR INHIBITOR 1; ROSUVASTATIN; SARPOGRELATE; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN RECEPTOR 2; STREPTOZOCIN; SUCCINIC ACID DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CELL PROLIFERATION; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DRUG EFFICACY; ENDOTHELIUM CELL; ENZYMURIA; EXTRACELLULAR MATRIX; IN VITRO STUDY; KIDNEY FIBROSIS; MALE; MESANGIUM CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RENAL PROTECTION; ADVERSE EFFECTS; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG EFFECTS; FIBROSIS; GENE EXPRESSION REGULATION; GENETICS; LIPID DIET; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC;

ANIMALS; CELL PROLIFERATION; DIET, HIGH-FAT; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; FIBROSIS; GENE EXPRESSION REGULATION; MALE; MESANGIAL CELLS; MICE; MICE, INBRED C57BL; PLASMINOGEN ACTIVATOR INHIBITOR 1; RENAL INSUFFICIENCY, CHRONIC; ROSUVASTATIN CALCIUM; STREPTOZOCIN; SUCCINATES;

EID: 84979022006     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0153965     Document Type: Article

References (62)

1. Eckardt KU, Coresh J, Devuyst O, Johnson RJ, Kottgen A, Levey AS, et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet (London, England). 2013; 382 (9887):158-69. Epub 2013/06/04. doi: 10.1016/s0140-6736(13)60439-0 PMID: 23727165.
2. Levey AS, Eckardt K-U, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney international. 2005; 67(6):2089-398. PMID: 15882252
3. Meguid El Nahas A, Bello AK. Chronic kidney disease: the global challenge. Lancet (London, England). 2005; 365(9456):331-40. Epub 2005/01/25. doi: 10.1016/s0140-6736(05)17789-7 PMID: 15664230.
4. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. Jama. 2007; 298(17):2038-47. Epub 2007/11/08. doi: 10.1001/jama.298.17.2038 PMID: 17986697.
5. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. American Journal of Kidney Diseases. 1998; 32(5):S112-S9. PMID: 9820470
6. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003; 108(17):2154-69. Epub 2003/10/29. doi: 10. 1161/01.cir.0000095676.90936.80 PMID: 14581387.
7. Jafar T, Islam M, Poulter N. Chronic kidney disease in the developing world. 2006.
8. Hovind P, Rossing P, Tarnow L, Smidt UM, Parving HH. Progression of diabetic nephropathy. Kidney international. 2001; 59(2):702-9. Epub 2001/02/13. doi: 10.1046/j.1523-1755.2001.059002702.x PMID: 11168952.
9. Gelber RP, Kurth T, Kausz AT, Manson JE, Buring JE, Levey AS, et al. Association between body mass index and CKD in apparently healthy men. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2005; 46(5):871-80. Epub 2005/10/29. doi: 10.1053/j.ajkd. 2005.08.015 PMID: 16253727.
10. Manttari M, Tiula E, Alikoski T, Manninen V. Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension. 1995; 26(4):670-5. Epub 1995/10/01. PMID: 7558229.
11. Suh DC, Choi IS, Plauschinat C, Kwon J, Baron M. Impact of comorbid conditions and race/ethnicity on glycemic control among the US population with type 2 diabetes, 1988-1994 to 1999-2004. Journal of diabetes and its complications. 2010; 24(6):382-91. Epub 2009/09/01. doi: 10.1016/j.jdiacomp.2009. 07.001 PMID: 19716320.
12. Braun L, Sood V, Hogue S, Lieberman B, Copley-Merriman C. High burden and unmet patient needs in chronic kidney disease. International journal of nephrology and renovascular disease. 2012; 5:151-63.Epub 2013/01/08. doi: 10.2147/ijnrd.s37766 PMID: 23293534; PubMed Central PMCID: PMCPmc3534533.
13. Fraser SD, Roderick PJ, May CR, McIntyre N, McIntyre C, Fluck RJ, et al. The burden of comorbidity in people with chronic kidney disease stage 3: a cohort study. BMC nephrology. 2015; 16:193. Epub 2015/12/02. doi: 10.1186/s12882-015-0189-z PMID: 26620131; PubMed Central PMCID: PMCPmc4666158.
14. Deji N, Kume S, Araki S-i, Soumura M, Sugimoto T, Isshiki K, et al. Structural and functional changes in the kidneys of high-fat diet-induced obese mice. American Journal of Physiology-Renal Physiology. 2009; 296(1):F118-F26. doi: 10.1152/ajprenal.00110.2008 PMID: 18971213
15. Shevalye H, Lupachyk S, Watcho P, Stavniichuk R, Khazim K, Abboud HE, et al. Prediabetic nephropathy as an early consequence of the high-calorie/high-fat diet: relation to oxidative stress. Endocrinology. 2012; 153(3):1152-61. doi: 10.1210/en.2011-1997 PMID: 22234462
16. Kuwabara T, Mori K, Mukoyama M, Kasahara M, Yokoi H, Saito Y, et al. Exacerbation of diabetic nephropathy by hyperlipidaemia is mediated by Toll-like receptor 4 in mice. Diabetologia. 2012; 55 (8):2256-66. Epub 2012/05/23. doi: 10.1007/s00125-012-2578-1 PMID: 22610400.
17. Srinivasan K, Viswanad B, Asrat L, Kaul CL, Ramarao P. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacological research. 2005; 52(4):313-20. Epub 2005/06/28. doi: 10.1016/j.phrs.2005.05.004 PMID: 15979893.
18. Liu Y. Cellular and molecular mechanisms of renal fibrosis. Nature reviews Nephrology. 2011; 7 (12):684-96. Epub 2011/10/20. doi: 10.1038/nrneph.2011.149 PMID: 22009250; PubMed Central PMCID: PMCPmc4520424.
19. Eddy AA. Molecular insights into renal interstitial fibrosis. Journal of the American Society of Nephrology. 1996; 7(12):2495-508. PMID: 8989727
20. Strutz F, Zeisberg M. Renal fibroblasts and myofibroblasts in chronic kidney disease. Journal of the American Society of Nephrology. 2006; 17(11):2992-8. PMID: 17035610
21. Böttinger EP, editor TGF-β in renal injury and disease. Seminars in nephrology; 2007: Elsevier.
22. Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney international. 2006; 69(2):213-7. Epub 2006/01/13. doi: 10.1038/sj.ki.5000054 PMID: 16408108.
23. Ghosh AK, Vaughan DE. PAI-1 in tissue fibrosis. Journal of cellular physiology. 2012; 227(2):493-507.Epub 2011/04/06. doi: 10.1002/jcp.22783 PMID: 21465481; PubMed Central PMCID: PMCPmc3204398.
24. Malgorzewicz S, Skrzypczak-Jankun E, Jankun J. Plasminogen activator inhibitor-1 in kidney pathology (Review). International journal of molecular medicine. 2013; 31(3):503-10. Epub 2013/01/15. doi: 10.3892/ijmm.2013.1234 PMID: 23314920.
25. Adly AA, Elbarbary NS, Ismail EA, Hassan SR. Plasminogen activator inhibitor-1 (PAI-1) in children and adolescents with type 1 diabetes mellitus: relation to diabetic micro-vascular complications and carotid intima media thickness. Journal of diabetes and its complications. 2014; 28(3):340-7. Epub 2014/03/04. doi: 10.1016/j.jdiacomp.2014.01.011 PMID: 24581943.
26. Alessi MC, Juhan-Vague I. PAI-1 and the metabolic syndrome: links, causes, and consequences. Arteriosclerosis, thrombosis, and vascular biology. 2006; 26(10):2200-7. Epub 2006/08/26. doi: 10.1161/01.atv.0000242905.41404.68 PMID: 16931789.
27. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet (London, England). 1987; 2 (8549):3-9. Epub 1987/07/04. PMID: 2885513.
28. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. The New England journal of medicine. 2000; 342(24):1792-801. Epub 2000/06/15. doi: 10.1056/ nejm200006153422406 PMID: 10853003.
29. Doggrell SA. The role of 5-HT on the cardiovascular and renal systems and the clinical potential of 5-HT modulation. Expert opinion on investigational drugs. 2003; 12(5):805-23. Epub 2003/05/02. doi: 10. 1517/13543784.12.5.805 PMID: 12720492.
30. Pakala R, Willerson JT, Benedict CR. Effect of serotonin, thromboxane A2, and specific receptor antagonists on vascular smooth muscle cell proliferation. Circulation. 1997; 96(7):2280-6. PMID: 9337201
31. Barradas MA, Gill DS, Fonseca VA, Mikhailidis DP, Dandona P. Intraplatelet serotonin in patients with diabetes mellitus and peripheral vascular disease. European journal of clinical investigation. 1988; 18 (4):399-404. Epub 1988/08/01. PMID: 3139426.
32. Hasegawa Y, Suehiro A, Higasa S, Namba M, Kakishita E. Enhancing effect of advanced glycation end products on serotonin-induced platelet aggregation in patients with diabetes mellitus. Thrombosis research. 2002; 107(6):319-23. Epub 2003/02/05. PMID: 12565718.
33. Saini HK, Takeda N, Goyal RK, Kumamoto H, Arneja AS, Dhalla NS. Therapeutic potentials of sarpogrelate in cardiovascular disease. Cardiovascular drug reviews. 2004; 22(1):27-54. Epub 2004/02/24.PMID: 14978517.
34. Sirtori CR. The pharmacology of statins. Pharmacological research. 2014; 88:3-11. Epub 2014/03/25. doi: 10.1016/j.phrs.2014.03.002 PMID: 24657242.
35. Campese VM. Dyslipidemia and progression of kidney disease: role of lipid-lowering drugs. Clinical and experimental nephrology. 2014; 18(2):291-5. Epub 2014/02/19. doi: 10.1007/s10157-014-0934-9PMID: 24535025.
36. Kasahara M, Nakagawa T, Yokoi H, Kuwabara T, Yasuno S, Mori K, et al. Do statins play a role in renoprotection? Clinical and experimental nephrology. 2014; 18(2):282-5. Epub 2014/01/11. doi: 10.1007/ s10157-013-0928-z PMID: 24408222.
37. Lee HS, Ku SK. Effect of Picrorrhiza rhizoma extracts on early diabetic nephropathy in streptozotocininduced diabetic rats. Journal of medicinal food. 2008; 11(2):294-301. Epub 2008/07/05. doi: 10.1089/ jmf.2007.578 PMID: 18598172.
38. Son JY, Kang YJ, Kim KS, Kim TH, Lim SK, Lim HJ, et al. Evaluation of renal toxicity by combination exposure to melamine and cyanuric Acid in male sprague-dawley rats. Toxicological research. 2014; 30(2):99-107. Epub 2014/07/30. PMID: 25071919; PubMed Central PMCID: PMCPmc4112071.
39. Kim TH, Hur EG, Kang SJ, Kim JA, Thapa D, Lee YM, et al. NRF2 blockade suppresses colon tumor angiogenesis by inhibiting hypoxia-induced activation of HIF-1alpha. Cancer research. 2011; 71 (6):2260-75. Epub 2011/02/01. doi: 10.1158/0008-5472.can-10-3007 PMID: 21278237.
40. Ryoo IG, Shin DH, Kang KS, Kwak MK. Involvement of Nrf2-GSH signaling in TGFbeta1-stimulated epithelial-to-mesenchymal transition changes in rat renal tubular cells. Archives of pharmacal research. 2015; 38(2):272-81. Epub 2014/05/23. doi: 10.1007/s12272-014-0380-y PMID: 24849033.
41. Ito M, Kondo Y, Nakatani A, Hayashi K, Naruse A. Characterization of low dose streptozotocin-induced progressive diabetes in mice. Environmental toxicology and pharmacology. 2001; 9(3):71-8. Epub 2001/02/13. PMID: 11167151.
42. Reidy K, Kang HM, Hostetter T, Susztak K. Molecular mechanisms of diabetic kidney disease. The Journal of clinical investigation. 2014; 124(6):2333-40. Epub 2014/06/04. doi: 10.1172/jci72271 PMID: 24892707; PubMed Central PMCID: PMCPmc4089448.
43. Cooper ME, Vranes D, Youssef S, Stacker SA, Cox AJ, Rizkalla B, et al. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes. 1999; 48(11):2229-39. Epub 1999/10/27. PMID: 10535459.
44. Tsuchida K, Makita Z, Yamagishi S, Atsumi T, Miyoshi H, Obara S, et al. Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. Diabetologia. 1999; 42(5):579-88. Epub 1999/ 05/20. doi: 10.1007/s001250051198 PMID: 10333051.
45. Abboud HE. Mesangial cell biology. Experimental cell research. 2012; 318(9):979-85. Epub 2012/03/15. doi: 10.1016/j.yexcr.2012.02.025 PMID: 22414873.
46. Landray MJ, Haynes RJ. Commentary: Controversies in NICE guidance on chronic kidney disease. BMJ (Clinical research ed). 2008; 337:a1793. Epub 2008/10/01. doi: 10.1136/bmj.a1793 PMID: 18824482.
47. Herget-Rosenthal S, Feldkamp T, Volbracht L, Kribben A. Measurement of urinary cystatin C by particle-enhanced nephelometric immunoassay: precision, interferences, stability and reference range. Annals of clinical biochemistry. 2004; 41(Pt 2):111-8. Epub 2004/03/18. doi: 10.1258/000456304322879980 PMID: 15025800.
48. Herget-Rosenthal S, Marggraf G, Husing J, Goring F, Pietruck F, Janssen O, et al. Early detection of acute renal failure by serum cystatin C. Kidney international. 2004; 66(3):1115-22. Epub 2004/08/26. doi: 10.1111/j.1523-1755.2004.00861.x PMID: 15327406.
49. Wasung ME, Chawla LS, Madero M. Biomarkers of renal function, which and when? Clinica chimica acta; international journal of clinical chemistry. 2015; 438:350-7. Epub 2014/09/10. doi: 10.1016/j.cca. 2014.08.039 PMID: 25195004.
50. Doggrell SA. Sarpogrelate: cardiovascular and renal clinical potential. Expert opinion on investigational drugs. 2004; 13(7):865-74. Epub 2004/06/24. doi: 10.1517/13543784.13.7.865 PMID: 15212624.
51. Kobayashi S, Satoh M, Namikoshi T, Haruna Y, Fujimoto S, Arakawa S, et al. Blockade of serotonin 2A receptor improves glomerular endothelial function in rats with streptozotocin-induced diabetic nephropathy. Clinical and experimental nephrology. 2008; 12(2):119-25. Epub 2008/01/05. doi: 10.1007/ s10157-007-0011-8 PMID: 18175064.
52. Hamasaki Y, Doi K, Maeda-Mamiya R, Ogasawara E, Katagiri D, Tanaka T, et al. A 5-hydroxytryptamine receptor antagonist, sarpogrelate, reduces renal tubulointerstitial fibrosis by suppressing PAI-1.American journal of physiology Renal physiology. 2013; 305(12):F1796-803. Epub 2013/10/11. doi: 10.1152/ajprenal.00151.2013 PMID: 24107419.
53. Takahashi T, Yano M, Minami J, Haraguchi T, Koga N, Higashi K, et al. Sarpogrelate hydrochloride, a serotonin2A receptor antagonist, reduces albuminuria in diabetic patients with early-stage diabetic nephropathy. Diabetes research and clinical practice. 2002; 58(2):123-9. Epub 2002/09/06. PMID: 12213354.
54. Ogawa S, Mori T, Nako K, Ishizuka T, Ito S. Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes. Clinical journal of the American Society of Nephrology: CJASN. 2008; 3(2):362-8. Epub 2008/02/01. doi: 10.2215/cjn.03450807 PMID: 18235151; PubMed Central PMCID: PMCPmc2390947.
55. Jagroop IA, Mikhailidis DP. Doxazosin, an alpha1-adrenoceptor antagonist, inhibits serotonin-induced shape change in human platelets. Journal of human hypertension. 2001; 15(3):203-7. Epub 2001/04/24. doi: 10.1038/sj.jhh.1001146 PMID: 11317206.
56. Kasho M, Sakai M, Sasahara T, Anami Y, Matsumura T, Takemura T, et al. Serotonin enhances the production of type IV collagen by human mesangial cells. Kidney international. 1998; 54(4):1083-92.Epub 1998/10/10. doi: 10.1046/j.1523-1755.1998.00114.x PMID: 9767524.
57. de Zeeuw D, Anzalone DA, Cain VA, Cressman MD, Heerspink HJ, Molitoris BA, et al. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. The lancet Diabetes & endocrinology. 2015; 3(3):181-90. Epub 2015/02/11. doi: 10.1016/s2213-8587(14)70246-3 PMID: 25660356.
58. Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP. Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction? Expert opinion on pharmacotherapy. 2015; 16(10):1449-61. Epub 2015/06/04. doi: 10.1517/ 14656566.2015.1053464 PMID: 26037614.
59. Tamura Y, Murayama T, Minami M, Yokode M, Arai H. Differential effect of statins on diabetic nephropathy in db/db mice. International journal of molecular medicine. 2011; 28(5):683-7. Epub 2011/08/13. doi: 10.3892/ijmm.2011.769 PMID: 21833465.
60. Giunti S, Calkin AC, Forbes JM, Allen TJ, Thomas MC, Cooper ME, et al. The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse. American journal of physiology Renal physiology. 2010; 299(3):F528-35. Epub 2010/06/18. doi: 10.1152/ajprenal.00127.2010PMID: 20554645.
61. Oda T, Jung YO, Kim HS, Cai X, Lopez-Guisa JM, Ikeda Y, et al. PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney international. 2001; 60(2):587-96. Epub 2001/07/28.doi: 10.1046/j.1523-1755.2001.030002587.x PMID: 11473641.
62. Krag S, Danielsen CC, Carmeliet P, Nyengaard J, Wogensen L. Plasminogen activator inhibitor-1 gene deficiency attenuates TGF-beta1-induced kidney disease. Kidney international. 2005; 68(6):2651-66.Epub 2005/12/01. doi: 10.1111/j.1523-1755.2005.00737.x PMID: 16316341.